GLP-1 & Type 2 Diabetes: the prescription is only half the story.r blog post

GLP-1 & Type 2 Diabetes: the prescription is only half the story. The next commercial battle is happening between the consult room and the consumer feed. Three signals should get every pharma, nutrition and digital-health leader’s attention: 21% of U.S. households now include a current GLP-1 user. 80% of current users say they use at least one supporting product alongside treatment. Yet only 23% feel well-supported by today’s wellness platforms. And the clinical direction is getting clearer. ADA’s 2026 Standards favour GLP-1 or dual GIP/GLP-1 therapy for adults with type 2 diabetes and overweight/obesity, while continuing nutrition, physical activity and behavioural support as part of care. That creates a very different intelligence problem. Ozempic. Rybelsus. Mounjaro. Trulicity. Victoza. The products are visible. What is harder to see is what HCPs recommend alongside them, what patients discuss on Reddit/TikTok, which nutrition products enter the routine, and where competitor influence starts before sales data shows it. That is the gap worth measuring. If you lead Brand, Medical, Commercial, Consumer Insights or Data in GLP-1/T2DM,- Write to us - info@apxmetrics.com The market is moving fast. Are you listening early enough?Blog post description.